Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
Hannah Cohen(University College Hospital), David Isenberg(UCL Australia), Nicola Muirhead(University College London), María Laura Bertolaccini(Guy's and St Thomas' NHS Foundation Trust), Beverley J. Hunt, Caroline J Doré(University College London), Ian Mackie(The Royal Free Hospital), Munther A. Khamashta(Women's & Children's Health Research Institute), Maria Ruiz-Castellano(St Thomas' Hospital), Deepa J. Arachchillage(Imperial College Healthcare NHS Trust), Yvonne Sylvestre(University College London), Samuel J. Machin(University College London), Simon Clawson(University College London), Maria Efthymiou(University College London)
Cited by 404
Related Papers
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
The “Primary” Antiphospholipid Syndrome
|Medicine|1989|963
Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies
|British Journal of Haematology|2012|861
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
|Annals of the Rheumatic Diseases|2014|726
Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis
|European Journal of Vascular and Endovascular Surgery|2020|709